Metoprolol Succinate Price Trend

Metoprolol Succinate Prices December 2023

In Q4 2023, metoprolol succinate prices in the United States reached 57740 USD/MT. During Q4, the metoprolol succinate market has shown significant fluctuations in prices amid economic pressures. December witnessed a significant price drop mainly driven by the declining demand from key sectors and waning consumer confidence. This led to an oversupply promoting manufacturers and distributors to lower the prices to offload excess inventory.

During Q4 2023, the Chinese market for metoprolol succinate has shown volatile conditions. Prices saw a moderate increase in October and November mainly driven by limited supplies and increased consumer demand during the festive season. In December prices fell because of decreased inquiries from downstream industries and sluggish export activities. In Q4 2023 price of metoprolol succinate reached 57015 USD/MT in China.

In Q4 2023 metoprolol succinate market reached 58665 USD/MT in Germany. The prices for metoprolol succinate were affected by the decline in demand from end users mainly in health care and pharmaceutical sectors and also due to abundant supply in the market.

Metoprolol Succinate Price Trend, Market Analysis, and News

IMARC’s newly published report, titled “Metoprolol Succinate Pricing Report 2024: Price Trend, Chart, Market Analysis, News, Demand, Historical and Forecast Data,” offers an in-depth analysis of metoprolol succinate pricing, covering an analysis of global and regional market trends and the critical factors driving these price movements.

It encompasses an in-depth review of spot price of metoprolol succinate at major ports, a breakdown of prices including Ex Works, FOB, and CIF, alongside a region-wise dissection of metoprolol succinate price trend across North America, Europe, Asia Pacific, Latin America, the Middle East and Africa.

The report examines the elements influencing metoprolol succinate price fluctuations, such as changes in raw material costs, supply-demand dynamics, geopolitical factors, and industry-specific developments. Additionally, it integrates the latest market news, providing stakeholders with up-to-date information on market shifts, regulatory changes, and technological advancements, thereby offering a comprehensive overview that aids in strategic decision-making and forecasting.

Metoprolol Succinate Market Analysis

The global metoprolol succinate market size reached 78.1 Thousand Tonnes in 2023. By 2032, IMARC Group expects the market to reach 105.5 Thousand Tonnes, at a projected CAGR of 3.40% during 2023-2032.

• The rising incidence of cardiovascular diseases such as hypertension, heart attacks, and arrhythmias significantly propel the demand for effective treatment options like metoprolol succinate. As these heart-related conditions are becoming more prevalent, mainly in aging populations and in the regions with increasing health awareness necessitates the need for reliable and accessible medications. According to a report by the World Health Organization (WHO), cardiovascular diseases are one of the leading causes of death globally. Approximately 17.9 million people die every year due to cardiovascular disease. Metoprolol succinate is generally known for its efficacy in managing these cardiovascular diseases. It is increasingly sought after both in established and emerging markets, thereby driving the metoprolol succinate market growth.
• The aging of the global population is also a significant factor influencing healthcare trends, mainly in the demand for medications such as beta-blockers, including metoprolol succinate. According to a report published by World Health Organization (WHO), by the year 2030, one in six people will be aged 60 years or older. Older people are more prone to develop chronic heart-related diseases like hypertension, arrhythmias, and heart failure. These conditions necessitate effective long-term management strategies for which beta blockers are the cornerstone treatment because of their proven efficacy in reducing heart strain and preventing complications thereby propelling the metoprolol succinate market growth.
• Moreover, public health initiatives launched by governments and non-governmental organizations aimed at combating heart disease significantly propelled the demand for medications like metoprolol succinate. These initiatives often include widespread screening programs to identify individuals at risk of cardiovascular conditions early in their progression. For instance, the Government of India has launched the National Program for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke (NPCDCS), which is implemented for interventions up to the district level under the National Health Mission. NPCDCS has a focus on awareness generation for behaviour and lifestyle changes, screening and early diagnosis of persons with high levels of risk factors, and their treatment and referral (if required) to higher facilities for appropriate management of Non-communicable Diseases (NCDs), including cardiovascular diseases. By catching heart issues early, these programs facilitate timely intervention, which typically includes the prescription of beta blockers among other treatments, thereby driving the metoprolol succinate market growth.

Metoprolol Succinate News

The report covers the latest developments, updates, and trends impacting the global metoprolol succinate market, providing stakeholders with timely and relevant information. This segment covers a wide array of news items, including the inauguration of new production facilities, advancements in metoprolol succinate production technologies, strategic market expansions by key industry players, and significant mergers and acquisitions that impact the metoprolol succinate price trend.

Latest developments in the metoprolol succinate industry:

• August 2023: Lupin Limited, a global pharmaceutical company, has received approval from the U.S. FDA to market a generic version of Toprol-XL® (metoprolol succinate extended-release tablets) in the United States. This product will be manufactured at Lupin's facility in India. The approval strengthens Lupin's position in the cardiovascular segment and demonstrates its commitment to expanding its portfolio of affordable generic medicines.
• March 2024: Zydus Healthcare has received approval from the Central Drugs Standard Control Organization (CDSCO) panel to study a fixed-dose combination (FDC) of empagliflozin and metoprolol succinate. The FDC is intended to treat type 2 diabetes and hypertension. The study will evaluate the safety, efficacy, and pharmacokinetics of the FDC compared to the individual drugs. This combination therapy could provide a convenient treatment option for patients with both conditions, potentially improving medication adherence and disease management.

Product Description

Metoprolol succinate is a beta-blocker medication that is primarily used to manage hypertension, angina, and heart rhythm disorders. It works by blocking the effects of adrenaline on the heart and blood vessels, thereby reducing heart rate, blood pressure, and strain on the heart. This drug is a more extended-release form of metoprolol, allowing for once-daily dosing. This feature can improve patient compliance compared to medications requiring multiple doses per day. Moreover, it is commonly prescribed after heart attacks to prevent further cardiac events. Additionally, metoprolol succinate can be used off-label to help control symptoms of anxiety and to prevent migraine headaches. Its role in managing these conditions makes it a versatile and vital medication in clinical medicine. The drug's effectiveness and safety profile have made it a cornerstone in the treatment of various heart-related ailments.

Regional Coverage

The report provides a detailed analysis of the metoprolol succinate market across different regions, each with unique pricing dynamics influenced by localized market conditions, supply chain intricacies, and geopolitical factors. This includes price trends, price forecast and supply and demand trends for each region, along with spot prices by major ports. The report also provides coverage of ex-works, FOB, and CIF prices, as well as the key factors influencing the metoprolol succinate price trend. 

Global Metoprolol Succinate Price

The report offers a holistic view of the global metoprolol succinate pricing trends in the form of metoprolol succinate price charts, reflecting the worldwide interplay of supply-demand balances, international trade policies, and overarching economic factors that shape the market on a macro level. This comprehensive analysis not only highlights current price of metoprolol succinate but also provides insights into historical price trends, enabling stakeholders to understand past fluctuations and their underlying causes.

The report also delves into price forecast models, projecting future price movements based on a variety of indicators such as expected changes in supply chain dynamics, anticipated policy shifts, and emerging market trends. By examining these factors, the report equips industry participants with the necessary tools to make informed strategic decisions, manage risks, and capitalize on market opportunities. Furthermore, it includes a detailed metoprolol succinate demand analysis, breaking down regional variations and identifying key drivers specific to each geographic market, thus offering a nuanced understanding of the global pricing landscape.

Europe Metoprolol Succinate Price

Metoprolol succinate prices in the European region were affected by several factors in Q4 2023. These included a decline in demand due to inflationary pressures and high interest rates, surplus supply, and Germany's market dynamics. The price trends showed a slight increase in November and a decrease in December, with no significant variation between the first and second halves of the quarter.

This analysis can be extended to include detailed metoprolol succinate price information for a comprehensive list of countries.

North America Metoprolol Succinate Price

During Q4 2023, North American metoprolol succinate prices declined due to weak demand caused by inflation and interest rates. Despite an increase in output and easing inflationary pressures, prices in the US fell in December due to lower demand and consumer confidence. Manufacturers and distributors responded by offering lower quotations to clear excess inventory. Overall, prices fluctuated based on demand-supply dynamics and the economic climate.

Specific metoprolol succinate historical data within the United States and Canada can also be provided.

Middle East and Africa Metoprolol Succinate Price

The report explores the metoprolol succinate pricing trends in the Middle East and Africa, considering factors like regional industrial growth, the availability of natural resources, and geopolitical tensions that uniquely influence market prices.

In addition to region-wise data, information on metoprolol succinate prices for countries can also be provided.

Asia Pacific Metoprolol Succinate Price

The metoprolol succinate market in the APAC region during Q4 2023 saw weak demand due to subdued new orders and purchases. Adequate supply led to stable pricing, but global uncertainties and geopolitical challenges created a cautious sentiment among market participants. China's metoprolol succinate market experienced moderate price increases in Oct-Nov due to constrained supplies and festive demand, but prices declined in Dec due to reduced inquiries and sluggish exports. Global supply chain disruptions due to tensions in the Red Sea also affected Asian exports.

This metoprolol succinate price analysis can be expanded to include a comprehensive list of countries within the region.

Latin America Metoprolol Succinate Price

The analysis of metoprolol succinate prices in Latin America provides a detailed overview, reflecting the unique market dynamics in the region influenced by economic policies, industrial growth, and trade frameworks.

This comprehensive review can be extended to include specific countries within the region.

Report Coverage

Key Benefits for Stakeholders:

• IMARC’s report presents a detailed analysis of metoprolol succinate pricing, covering global and regional trends, spot prices at key ports, and a breakdown of Ex Works, FOB, and CIF prices.
• The study examines factors affecting metoprolol succinate price trend, including raw material costs, supply-demand shifts, geopolitical impacts, and industry developments, offering insights for informed decision-making.
• The competitive landscape review equips stakeholders with crucial insights into the latest market news, regulatory changes, and technological advancements, ensuring a well-rounded, strategic overview for forecasting and planning.
• IMARC offers various subscription options, including monthly, quarterly, and biannual updates, allowing clients to stay informed with the latest market trends, ongoing developments, and comprehensive market insights. The metoprolol succinate price charts ensure our clients remain at the forefront of the industry.